Department of Biomedical Sciences, SNU
KOR

Faculty

  1. Home
  2. Faculty
  3. Faculty

Faculty

Kim, jeong-hun

M.D., Ph.D. / Professor
Fight against Angiogenesis-Related Blindness (FARB) Laboratory
TEL +82-2-740-8387
FAX 02-741-3187
E-MAIL steph25@snu.ac.kr
WEBSITE 없음

Research

Research Field
Professor Jeong Hoon Kim runs the Fight-against Angiogenesis-Related Blindness (FARB) laboratory, consisting of 13 researchers, including one associate professor, two research professors, and ten researchers, including three clinical doctors.
Research fields include molecular mechanisms focusing on the blood-retinal barrier and retinal neovascularization, and preclinical studies using animal models for age-related macular degeneration, diabetic retinopathy, retinopathy prematurity, and retinoblastoma, and translational research across clinical studies in patients.

Fight against Angiogenesis-Related Blindness (FARB) Laboratory (Major Research Interests)
[1] Translational research on vision threatening eye diseases: retinopathy of prematurity, diabetic retinopathy, uveitis, age-related macular degeneration
[2] Tumor biology in retinoblastoma
[3] Drug development for vision threatening eye diseases: small molecule, peptide, antibody, RNA therapeutics, gene therapy, genome editing, cell therapy
Pure Link
https://snucm.elsevierpure.com/en/persons/jeong-hun-kim
Keyword
Retinal & Choroidal Angiogenesis; Blood-retinal Barrier; Retinopathy of Prematurity; Diabetic Retnopathy; Age-related Macular Degeneration; Retinoblastoma
Intensive Major
# Physiology-Neurology

Education

  • Mar. 1992 - Feb. 1998 Seoul National University College of Medicine, Seoul, Korea (MD)
  • Sep. 2001 - Feb. 2006 Postgraduate School, Seoul National University, Seoul, Korea (Ph.D. in Dept. of Ophthalmology)

Career

  • May 2007. - present. Clinical Professor in Dept. of Ophthalmology, Seoul National University Hospital, Seoul, Korea
  • Sep 2010. - present. Assistant Professor/ Associate Professor/ Professor in Dept. of Biomedical Science & Dept. of Clinical Science, Seoul National University College of Medicine, Seoul, Korea

Publication

  1. [1] Jang HK, Jo DH, Lee SN, Cho CS, Jeong YK, Jung Y, Yu J, Kim JH*, Woo JS*, Bae S*. High-purity production and precise editing of DNA base editing ribonucleoproteins. Sci Adv. 2021 Aug 27;7(35):eabg2661. doi: 10.1126/sciadv.abg2661. PubMed PMID:34452911. (*Corresponding author)
  2. [2] Jang H, Jo DH, Cho CS, Shin JH, Seo JH, Yu G, Gopalappa R, Kim D, Cho SR, Kim JH*, Kim HH*. Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases. Nat Biomed Eng. 2021 Aug 26. doi: 10.1038/s41551-021-00788-9. PubMed PMID:34446856. (*Corresponding author)
  3. [3] Jo DH, Song DW, Cho CS, Kim UG, Lee KJ, Lee K, Park SW, Kim D, Kim JH, Kim JS, Kim S, Kim JH*, Lee JM*. CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis. Sci Adv. 2019 Oct 30;5(10):eaax1210. doi: 10.1126/sciadv.aax1210. eCollection 2019 Oct. PubMed PMID: 31692906; PubMed Central PMCID: PMC6821465. (*Corresponding author)
  4. [4] Koo T, Park SW, Jo DH, Kim D, Kim JH, Cho HY, Kim J, Kim JH*, Kim JS*. CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration. Nat Commun. 2018 May 10;9(1):1855. doi: 10.1038/s41467-018-04175-y. PubMed PMID: 29748595; PubMed Central PMCID: PMC5945874. (*Corresponding author)
  5. [5] Kim E, Koo T, Park SW, Kim D, Kim K, Cho HY, Song DW, Lee KJ, Jung MH, Kim S, Kim JH, Kim JH*, Kim JS*. In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat Commun. 2017 Feb 21;8:14500. doi: 10.1038/ncomms14500. PubMed PMID: 28220790. (*Corresponding author)
List
KOREAN